Mar
30
2023
On demand
A platform approach to tackling AAV potency
Thursday 14:07 IST / 16:37 +08 / 17:37 KST / 17:37 JST / 16:37 AWST / 21:37 NZDT
Sponsor
AAV gene therapy products have complex mechanisms of action that pose unique challenges to potency assay development. Determining the true biological activity often requires multiple assays (i.e., a matrix approach), and the strategy for implementing these assays may evolve throughout the product lifecycle.
Join us as we discuss our strategy for potency assay development and how a platform approach can set you up for success.
- Hear about common challenges in AAV potency development
- What is a matrix approach?
- Learn about our platform methods that enable rapid development of phase-appropriate potency assays.
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Emily Neil, Ariadna Pascual
27 June
in 69
Days
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Adam Crowe
29 May
in 40
Days
Empowering patient care: in-process and quality control solutions for cellular therapies
Christin Tischner, Simon Lennartz
23 May
in 34
Days
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
Meredith Safford, ShaNelle Yelity
22 May
in 33
Days
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time
Emily Jackson-Holmes
21 May
in 32
Days